Yongrong Lai
机构：Guangxi University, Nankai University, Beihai People's Hospital, First Affiliated Hospital of GuangXi Medical University · ORCID：0000-0002-0371-1719
发表论文 105 篇 · 总被引 1821 次 · h-index 21
代表论文
- Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 27)
- In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery (2025 · Nature Biomedical Engineering · 被引 13)
- Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004) (2025 · JHEP Reports · 被引 7)
- Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Transfusion-Dependent Thalassemia: A Systematic Review and Meta-Analysis (2024 · Transplantation and Cellular Therapy · 被引 7)
- Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a multi-center study (2025 · Liver Cancer · 被引 6)
- In vivo genome editing of human hematopoietic stem cells for treatment of blood disorders by mRNA delivery (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 6)